AB-1005

Phase 2Small molecule

AAskBio Inc

AB-1005 is one of 48 small molecule programs targeting Parkinson disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson DiseaseNot yet recruiting

PARKINSON DISEASE (disorder)Not yet recruiting

Parkinson DiseasePhase 2

Not yet recruiting

PARKINSON DISEASE (disorder)Phase 2

Not yet recruiting

Competition

Competitive Landscape

91 competitors in Parkinson Disease

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

1 2

Brintellix

Takeda

Approved

1 3

Exelon

Novartis

Approved

1 4

Northera

Lundbeck

Approved

1 5

Myrbetriq

Astellas

Approved

1 6

Medrol

Pfizer

Approved

1 7

Keppra

UCB

Approved

—8

Nourianz

Kyowa Kirin Co., Ltd.

Ritalin

Epidiolex

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

PARKINSON DISEASE (disorder)

NCT07215403

Q4 2032

Phase 2Not yet recruiting

Parkinson Disease

NCT07566429

Clinical

Trials by Indication[1]

PARKINSON DISEASE (Disorder)1 trial

Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

Not yet recruiting·AAskBio Inc·Phase 2·NCT07215403·18 enrolled

Parkinson disease1 trial

A Phase 2, Open-label, Single Group, Fixed-dose Study to Evaluate the Safety and Efficacy of a Single Bilateral Intraputaminal Administration of AB-1005 (AAV2-GDNF Gene Therapy) in Japanese Participants With Moderate Stage Parkinson's Disease

Not yet recruiting· Bayer logo

Bayer·Phase 2·NCT07566429·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AB-1005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AB-1005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AB-1005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AskBio Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAskBio Inc

AB-1005

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q4 2032

Trials by Indication[1]

PARKINSON DISEASE (Disorder)1 trial

Parkinson disease1 trial

References

Drug Info

Quick Facts

Related News